Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
An opioid receptor agonizing and functional technology, applied in the field of medicine, can solve undiscovered problems, achieve good hypoglycemic effect, promote activation, and enhance the effect of adiponectin and insulin sensitivity
Inactive Publication Date: 2011-12-07
FOURTH MILITARY MEDICAL UNIVERSITY
View PDF0 Cites 3 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0006] At present, the research on U50, 488H has found that it has the effects of analgesia, sedation, and anti-inflammation, but it has not been found that it has the effect of lowering blood sugar and treating diabetes
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0031] Preparation method of injection medicine for treating diabetes with κ-opioid receptor agonist U50, 488H as active ingredient:
[0032] The sterile powder of κ-opioid receptor agonist U50, 488H is directly used as injection, and each injection contains 50mg-80mg of κ-opioid receptor agonist U50, 488H.
[0033] The usage and dosage of the injection is as follows: dissolve and dilute with 1mL-2.5mL of water for injection or sterile normal saline to form an injection, and inject one intramuscularly every day.
Embodiment 2
[0035] Preparation method of capsule drug for treating diabetes with κ-opioid receptor agonist U50, 488H as active ingredient:
[0036] The κ-opioid receptor agonist U50, 488H is made into capsules according to the conventional capsule-making method, and the carrier is a conventional pharmaceutical capsule carrier, each capsule is 0.1g to 0.25g, and each capsule contains the κ-opioid receptor agonist U50 , 488H 50mg ~ 80mg.
[0037] The usage and dosage of the capsules are as follows: take after meals, 1-2 times a day, 1-2 capsules each time.
Embodiment 3
[0039] Preparation method of tablet medicine for treating diabetes with κ-opioid receptor agonist U50, 488H as active ingredient:
[0040] The kappa-opioid receptor agonist U50, 488H is made into tablets according to the conventional tablet-making method, and the auxiliary materials are conventional pharmaceutically acceptable auxiliary materials (such as starch, magnesium stearate, dextrin, etc.), 0.25g per tablet ~0.5g, each tablet contains 50mg~80mg of κ-opioid receptor agonist U50, 488H.
[0041] The usage and dosage of the tablet is as follows: take after meal, 1-2 times a day, 1-2 tablets each time.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention discloses an application of kappa-opioid receptor agonists U50 and 488H in preparation of drugs for treating diabetes. In the invention, the good blood sugar reducing effect of kappa-opioid receptor agonists U50 and 488H is creatively discovered, and the research shows that the blood sugar reducing mechanisms of kappa-opioid receptor agonist U50 and 488H are as follows: (1) increasing the level of skeletal muscle adiponectin receptor 1 (AdipoR1) and enhancing the sensitivity of adiponectin and insulin; (2) promoting the membrane translocation of glucose transporter (GLUT4) in skeletal muscle cell and increasing the glucose transport capability of the skeletal muscle cell; and (3) promoting the activation of AMPK (adenosine-monophosphate-activated protein kinase) in the skeletal muscle cell and enhancing insulin sensitivity. In the invention, a new option is provided for the preparation of the drugs for treating diabetes.
Description
technical field [0001] The invention belongs to the technical field of medicine, and specifically relates to a new application of a κ-opioid receptor agonist, in particular to a new application of a κ-opioid receptor agonist U50,488H. Background technique [0002] Diabetes is a global public health problem with rapid development and great harm to people's health. Diabetes mellitus is a chronic systemic metabolic disease characterized by persistent high blood sugar as its basic biochemical feature. Hyperglycemia is a sign of diabetes, and decreased insulin levels or insulin sensitivity are the causes of diabetes. Therefore, reducing blood glucose levels by improving insulin sensitivity is an important target for the treatment of diabetes. [0003] As an insulin hypersensitizing hormone, adiponectin can increase and promote the fatty acid oxidation and sugar absorption of skeletal muscle cells, significantly strengthen the gluconeogenesis of insulin, inhibit the glycogenesis ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more